Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 86,061	$ 144,761
Accounts receivable, net	107,746	80,142
Inventories, net	114,466	94,491
Prepaid clinical development costs	4,170	586
Prepaid Inventory Costs	24,772	13,863
Other prepaid and current assets	5,380	4,155
Total current assets	342,595	337,998
Property and equipment, net	201	254
Right of use operating lease assets	4,233	5,513
Intangible assets	56	56
Total assets	347,085	343,821
Current liabilities:
Accounts payable	74,704	51,650
Convertible notes, net of issuance costs	54,766	54,575
Accrued clinical development costs	1,209	5,035
Accrued variable consideration	61,299	56,535
Other accrued liabilities	15,455	19,593
Royalty sale liability	66,312	47,586
Deferred revenue from collaborations	22,313	8,518
Operating lease liabilities	2,738	2,741
Total current liabilities	298,796	246,233
Convertible notes, net of issuance costs	96,998	96,745
Royalty sale liability	229,600	246,024
Long-term debt	146,452	140,971
Operating lease liabilities	1,312	2,570
Other long-term liabilities	7,436	0
Total liabilities	780,594	732,543
Commitments and contingencies (Note 5)
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June 30, 2025 and December 31, 2024	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 202,149,464 shares issued at June 30, 2025 and 197,846,661 shares issued at December 31, 2024	200	196
Additional paid-in capital	1,275,498	1,267,109
Treasury stock, at cost; 1,994,198 shares at June 30, 2025 and December 31, 2024	(54,998)	(54,998)
Accumulated deficit	(1,654,209)	(1,601,029)
Total stockholders’ deficit	(433,509)	(388,722)
Total liabilities and stockholders’ deficit	$ 347,085	$ 343,821
Common stock, authorized (in shares)	480,000,000	480,000,000